Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 8.15 GBp
Change Today +0.15 / 1.88%
Volume 1.6M
OXB On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 11:35 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

oxford biomedica plc (OXB) Snapshot

Open
7.75 GBp
Previous Close
8.00 GBp
Day High
8.15 GBp
Day Low
7.75 GBp
52 Week High
03/20/15 - 13.25 GBp
52 Week Low
09/4/14 - 3.45 GBp
Market Cap
209.7M
Average Volume 10 Days
2.8M
EPS TTM
-0.0039 GBp
Shares Outstanding
2.6B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OXFORD BIOMEDICA PLC (OXB)

Related News

No related news articles were found.

oxford biomedica plc (OXB) Related Businessweek News

No Related Businessweek News Found

oxford biomedica plc (OXB) Details

Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing RetinoStat that has completed Phase I trial for ‘wet’ age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease and OXB-102 that is in Phase I/II trials preparation for the treatment of Parkinson's disease; and MoNuDin, which is in pre-clinical stage for the treatment of motor neuron disease. In addition, the company is developing TroVax that is in Phase II trial for colorectal cancer, ovarian cancer, and mesothelioma; Anti-5T4 antibody, which is in Phase I trial for the treatment of cancer; and CAR-T 5T4, a combination of LentiVector and 5T4 platform. It has collaborations with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb, and Immune Design Corp. Oxford BioMedica plc was founded in 1995 and is based in Oxford, the United Kingdom.

192 Employees
Last Reported Date: 08/27/15
Founded in 1995

oxford biomedica plc (OXB) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 641.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 408.0K GBP
Chief Business Officer and Executive Director
Total Annual Compensation: 355.0K GBP
Chief Development Officer, Executive Director...
Total Annual Compensation: 140.0K GBP
Compensation as of Fiscal Year 2014.

oxford biomedica plc (OXB) Key Developments

Oxford BioMedica plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended 30 June 2015; Provides Capital Expenditure Guidance for the Second Half of 2015

Oxford BioMedica plc announced unaudited consolidated earnings results for the six months ended 30 June 2015. Revenue was £4,382,000 compared to £4,727,000 a year ago. Operating loss was £8,272,000 compared to £5,418,000 a year ago. Loss before tax was £8,600,000 compared to £5,624,000 a year ago. Loss for the period was £6,125,000 or 0.24 pence basic and diluted share compared to £4,801,000 or 0.32 pence basic and diluted share a year ago. Net cash used in operating activities was £9,239,000 compared to £4,967,000 a year ago. Purchase of property, plant and equipment was £4,644,000 compared to £50,000 a year ago. Capital expenditure will increase in the second half of 2015 as the group completes the Yarnton facility and continues with the current Harrow House expansion phase. Most of the work on the Windrush Court laboratories is also expected to be carried out during the next six months.

Oxford BioMedica PLC to Report First Half, 2015 Results on Aug 27, 2015

Oxford BioMedica PLC announced that they will report first half, 2015 results on Aug 27, 2015

Oxford BioMedica PLC, H1 2015 Earnings Call, Aug 27, 2015

Oxford BioMedica PLC, H1 2015 Earnings Call, Aug 27, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXB:LN 8.15 GBp +0.15

OXB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €12.60 EUR +0.075
Pharming Group NV €0.30 EUR -0.01
Swedish Orphan Biovitrum AB kr108.00 SEK +1.30
Medicines Co/The $39.87 USD +6.23
Veloxis Pharmaceuticals A/S kr1.05 DKK +0.01
View Industry Companies
 

Industry Analysis

OXB

Industry Average

Valuation OXB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.0x
Price/Book 8.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXFORD BIOMEDICA PLC, please visit www.oxfordbiomedica.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.